Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19184987 | 1.00 | MMP1 (0.47) | MMP1MMP3MMP7PTPN1MAPT | |
| SCHEMBL15116525 | 0.81 | CYP3A4 (0.57) | — | |
| SCHEMBL19388323 | 0.81 | PRCP (0.41) | MMP1MMP3MMP7 | |
| SCHEMBL15116536 | 0.81 | PRCP (0.41) | MMP1MMP3MMP7 | |
| SCHEMBL15111977 | 0.79 | MMP1 (0.39) | MMP1MMP3MMP7 | |
| SCHEMBL13758689 | 0.79 | SSTR3 (0.50) | MMP1MMP3MMP7 | |
| SCHEMBL13758829 | 0.79 | SSTR3 (0.50) | MMP1MMP3MMP7 | |
| SCHEMBL13294146 | 0.79 | SSTR3 (0.50) | MMP1MMP3MMP7 | |
| SCHEMBL18438936 | 0.78 | MMP1 (0.49) | MMP1MMP3MMP7MAPT | |
| SCHEMBL18438938 | 0.78 | MMP1 (0.49) | MMP1MMP3MMP7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9717712-B2 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2015026454-A1 | COMBINATIONS COMPRISING TRICYCLOHEXADECAHEXAENE DERIVATIVES FOR USE IN THE TREATMENT OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015009744-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | HAVCR2, EIF2AK2, MAVS | MMP1 4628/4885MMP3 4053/4885MMP7 2858/4885 |
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | HAVCR2, HCCS, MAVS | MMP1 4739/4885MMP3 4074/4885MMP7 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.